Prostate cancer antigen 3 as a biomarker in the urine for prostate cancer diagnosis: A meta-analysis

Journal of Cancer Research and Therapeutics

Volumn 10, Issue , 2014, Pages C218-C221

  Xue, Wu Jin ^a   Ying, Xiu Li ^a   Jiang, Jin Hong ^a   Xu, Ye Hui ^a  

^a LISHUI PEOPLE S HOSPITAL   (China)

Author keywords

Diagnosis; meta analysis; prostate cancer gene 3; prostate specific antigen

Indexed keywords

BIOLOGICAL MARKER; PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; PROSTATE CANCER ANTIGEN 3, HUMAN; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CLINICAL TRIAL (TOPIC); DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GOLD STANDARD; HUMAN; MALE; META ANALYSIS; NON INVASIVE PROCEDURE; PROSTATE CANCER; PROTEIN URINE LEVEL; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; URINALYSIS; AGED; AREA UNDER THE CURVE; MIDDLE AGED; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; URINE;

AGED; ANTIGENS, NEOPLASM; AREA UNDER CURVE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84916638772     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.145881     Document Type: Article

References (21)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Maria T, Panagiotis A, Marina C, Eleni K, Ioanna V, Georgia M, et al. How prostate-specific membrane antigen level may be correlated with stemness in prostate cancer stem cell-like cell populations? J Cancer Res Ther 2014;10:133-41.
3. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
4. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
5. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-15.
6. Fradet Y, Saad F, Aprikian A, Dessureault J, Elhilali M, Trudel C, et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 2004;64:311-5.
7. van Gils MP, Hessels D, van Hooij O, Jannink SA, Peelen WP, Hanssen SL, et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res 2007;13:939-43.
8. van Gils MP, Cornel EB, Hessels D, Peelen WP, Witjes JA, Mulders PF, et al. Molecular PCA3 diagnostics on prostatic fluid. Prostate 2007;67:881-7.
9. Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SM, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007;69:532-5.
10. Laxman B, Morris DS, Yu J, Siddiqui J, Cao J, Mehra R, et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 2008;68:645-9.
11. Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: Implication in selecting candidates for active surveillance. J Urol 2008;179:1804-9
12. Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, et al. PCA3: A molecular urine assay for predicting prostate biopsy outcome. J Urol 2008;179:1587-92.
13. Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008;54:1081-8.
14. Wang R, Chinnaiyan AM, Dunn RL, Wojno KJ, Wei JT. Rational approach to implementation of prostate cancer antigen 3 into clinical care. Cancer 2009;115:3879-86.
15. Shappell SB, Fulmer J, Arguello D, Wright BS, Oppenheimer JR, Putzi MJ. PCA3 urine mRNA testing for prostate carcinoma: Patterns of use by community urologists and assay performance in reference laboratory setting. Urology 2009;73:363-8.
16. Ouyang B, Bracken B, Burke B, Chung E, Liang J, Ho SM. A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer. J Urol 2009;181:2508-13.
17. Liu YL, Long-Ya WD, He J, Jun HJ, Cen JN, Pu JX. Gene expression of PCA3 in peripheral blood and urine and the significance of urine PCA3 score indiagnosis of prostate cancer. Chin J Urol 2012;33:278-81.
18. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-9.
19. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009 26;360:1320-8.
20. Loeb S, Partin AW. PCA3 Urinary Biomarker for Prostate Cancer. Rev Urol 2010;12:e205-6.
21. Linden A. Measuring diagnostic and predictive accuracy in disease management: An introduction to receiver operating characteristic (ROC) analysis. J Eval Clin Pract 2006;12:132-9.